- Report
- February 2022
- 50 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Drug Pipelines
- July 2020
- 61 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- October 2024
- 83 Pages
Global
From €3500EUR$3,944USD£3,043GBP
Beta Nerve Growth Factor (beta-NGF) is a protein that is involved in the growth and maintenance of neurons in the central nervous system. It is a member of the nerve growth factor family, which is responsible for the development and survival of neurons. Beta-NGF is used in the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). It is also used to treat peripheral neuropathy, a condition in which the peripheral nerves become damaged.
Beta-NGF is used in combination with other drugs to treat central nervous system disorders. It is believed to help protect neurons from damage and promote their growth and survival. It is also thought to help reduce inflammation and improve nerve conduction.
The market for beta-NGF is growing as more drugs are developed to treat neurological disorders. Companies such as AbbVie, Biogen, and Merck are involved in the development and marketing of beta-NGF drugs. Other companies such as Novartis, Pfizer, and Sanofi are also involved in the development and marketing of beta-NGF drugs. Show Less Read more